Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Delgado, Cindy
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	07/25	07/25
TEST, NCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant	Recruiting	N/A	360	US	TEST Intervention	University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence	07/26	01/27
Burdine, Mandy
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	NA	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	07/25	07/25